Moderna today asked the Food and Drug Administration to grant full approval of its COVID-19 vaccine for people age 18 years and older. So far, 124 million doses of the Moderna vaccine have been administered in the U.S. Moderna’s request for a priority review of its Biologics License Application includes data submitted on a rolling basis culled from its ongoing phase 3 clinical trial. Moderna is currently tracking about three weeks behind Pfizer, whose application for full FDA approval of its own COVID-19 vaccine was submitted May 7.

Related News Articles

Headline
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention…
Headline
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969…
Headline
The Health Resources and Services Administration Oct. 21 will host the last in a series of webinar sessions on how to apply for a portion of $25.5 billion…
Headline
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19…
Headline
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…